Guidance from 2014 consensus document (ESC / EHRA / EAPCI / ACCA / HRS / APHRS) 1 In patients with stable vascular disease (e.g.
{"Image DocumentName": "Guidance from 2014 consensus document (ESC / EHRA / EAPCI / ACCA / HRS / APHRS)1", "Image ImageDescription": "In patients with stable vascular disease (e.g. with no acute ischaemic events or PCI/stent procedure in the preceding 1 year), OAC monotherapy (well-controlled VKA or a NOAC) should be used, and concomitant antiplatelet therapy should not be prescribed on a routine basis. Combination of OAC plus single antiplatelet therapy (preferably clopidogrel 75 mg/day, or as an alternative, aspirin 75\u2013100 mg/day) may be sometimes continued in very selected cases, e.g. stenting of the left main, proximal left anterior descending, proximal bifurcation, recurrent MIs, etc. ESC: European Society of Cardiology; EHRA: European Heart Rhythm Association; EAPCI: European Association of Percutaneous Cardiovascular Interventions; ACCA: European Association of Acute Cardiac Care; HRS: Heart Rhythm Society; APHRS: Asia-Pacific Heart Rhythm Society. 1. Lip et al. European Heart Journal; first published online August 25, 2014.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}